copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Yeztugo Lenacapavir Is Now the First and Only FDA Approved . . . FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the U S Food and Drug Administration (FDA) has approved Yeztugo ® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice
FDA approves lenacapavir as a twice-a-year shot to prevent . . . A pharmacist holds a vial of lenacapavir, an injectable HIV prevention drug, at the Desmond Tutu Health Foundation’s Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, 2024, which was one of the sites for Gilead’s lenacapavir drug trial (AP Photo Nardus Engelbrecht, File)
HIV prevention drug lenacapavir approved by FDA as twice . . . What to know about the Trump administration's move to cut HIV vaccine research funding 02:33 The U S Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to
FDA approves twice-a-year injection for HIV prevention - CNN Lenacapavir is the latest HIV prevention shot to receive FDA approval Apretude , made by GSK’s ViiV Healthcare, was the first injectable pre-exposure prophylaxis medication to receive approval
HIV prevention drug hailed as a breakthrough gets FDA approval A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV
FDA approves new twice-yearly HIV shot. What to know The Food and Drug Administration on Wednesday approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections Gilead did